Pharmaceutics 14 , 2588 (2022)
Despite currently available therapeutics and advancements in the clinical management of heart failure and its associated complications, many challenges still remain as morbidity and mortality rates are showing no signs of decrease, (Tsao et al, 2022) highlighting unmet medical need to develop novel disease-modifying therapies for this disease
Cigna added that another factor in its MLR performance was higher-than-expected stop-loss costs, according to the earnings report
First, it removes excess abdominal skin that has permanently lost its elasticity following pregnancy, major weight loss or ageing
How it works: It acts directly on the mitochondria, restoring energy efficiency and reducing cellular inflammation
All authors approved the final version of this manuscript